Neurogen Corporation

Council of Scientific & Industrial Research

Vinod Kumar Singh

Alan J Hutchison

Jun Yuan

Pamela Ann Albaugh

George D Maynard

Manuka Ghosh

Guiying Li

Nian Liu

Kevin S Currie

Scott A Mitchell

Linda M Gustavson

Guolin Cai

John M Peterson

Kyungae Lee

Linghong Xie

Ehrlich Desa

Anil Chatterji

Ling Hong Xie

Parameswaran Perunninakulath Subrayan

Ramasamy Vijaya Anand

Gyan Chandra Mishra

Kanury Venkata Subba Rao

Mohan Ramachandran Wani

Venkatasamy Manivel

This invention relates to a novel class of acidic amino acid/dicarboxylic acid derivatives (sulfonic acid/sulfate derivatives of naturally occurring amino acids and their amides) useful as inhibitors of osteoclastogenesis. The invention also provides methods of using the novel class of acidic amino acid/dicarboxylic acid derivatives of the general formula ZOC&#x2014;(CRR)&#x2014;COOH, wherein: m=2, 3 or 4; Z is OH or NH; one R in the compound is from the group consisting of SOH, OSOH, CH&#x2014;SOH, CH&#x2014;OSOH, and NHSOH, and the remaining Rs are H or NH, for inhibition of osteoclastogenesis.

Method and composition for treating osteoporosis

This invention relates to heteroaryl substituted fused bicyclic heteroaryl compounds, such as heteroaryl substituted imidazopyridines, imidazopyrazines, imidazopyridizines, imidazopyrimidines, and imidazothiazoles, which may be described by Formula I or Formula II: The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAreceptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Processes for preparing compounds of Formula I and Formula II are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I or Formula II in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAreceptors in tissue sections.

Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands

This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAreceptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAreceptors in tissue sections.

Benzimidazole and pyridylimidazole derivatives

Growing community of inventors

Kanpur, India

Vinod Kumar Singh